Compare NVRI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVRI | PCRX |
|---|---|---|
| Founded | 1853 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.0M | 1.0B |
| IPO Year | N/A | 2011 |
| Metric | NVRI | PCRX |
|---|---|---|
| Price | $17.80 | $26.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.86 |
| AVG Volume (30 Days) | ★ 2.3M | 723.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $2,244,061,000.00 | $716,791,000.00 |
| Revenue This Year | N/A | $6.24 |
| Revenue Next Year | $3.42 | $9.53 |
| P/E Ratio | ★ N/A | $55.78 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $4.72 | $18.17 |
| 52 Week High | $18.74 | $27.64 |
| Indicator | NVRI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 71.78 | 73.86 |
| Support Level | $17.97 | $25.17 |
| Resistance Level | $18.29 | $24.81 |
| Average True Range (ATR) | 0.28 | 0.94 |
| MACD | -0.15 | 0.28 |
| Stochastic Oscillator | 0.56 | 89.16 |
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.